Answers are grounded in this paper and cite their sources.
Background/Objectives: Evidence on the prognostic significance of serum zinc in advanced pancreatic cancer (APC) and biliary tract cancer (BTC) is limited. We assessed the prognostic significance of serum zinc deficiency at baseline and 3 months in APC and BTC. Methods: This post hoc analysis of a prospective observational cohort included 134 patients with APC and 41 with BTC. Zinc deficiency was defined as serum zinc < 60 μg/dL. Overall survival (OS) was evaluated from baseline and from a fixed 3-month landmark using Kaplan–Meier and Cox regression analyses. Results: Baseline zinc deficiency was present in 13/134 (10%) patients with APC and 9/41 (22%) with BTC and was not significantly associated with OS in either cohort. At 3 months, zinc deficiency was present in 25/90 (28%) patients with APC and 15/33 (45%) with BTC and was associated with shorter subsequent OS (APC: 5.2 vs. 13.8 months, p < 0.001; BTC: 3.7 vs. 14.9 months, p = 0.006). Among patients with normal baseline zinc, new deficiency at 3 months was associated with shorter subsequent OS in both cohorts. In APC, zinc deficiency remained associated with OS after adjustment for performance status, tumor location, disease control, hypoalbuminemia, and C-reactive protein (HR, 1.93; 95% CI, 1.12–3.32). The coexistence of zinc deficiency and hypoalbuminemia was associated with poorer survival than the presence of neither abnormality (adjusted HR, 2.59; 95% CI, 1.22–5.52). Conclusions: Zinc deficiency, defined by the clinical threshold of <60 μg/dL at the 3-month landmark but not at baseline, was associated with shorter subsequent survival in APC and BTC. Assessment of serum zinc during treatment may contribute to prognostic evaluation.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: